Disease · MONDO_0008219
Comparisons in its trials22
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 22
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Efgartigimod PH20 SC vs Placebo PH20 SC: Number of Pemphigus Vulgaris (PV) and Pemphigus Foliaceus (PF) Participants Who Achieve Complete Clinical Remission (CR) on Minimal Prednisone Therapy Within 30 Weeks | 55 of 147 | 24 of 75 | 222 | NCT04598451 | Trial comparisons |
| Efgartigimod PH20 SC vs Placebo PH20 SC: deaths from any cause | 0 of 147 | 0 of 75 | 222 | NCT04598451 | Trial comparisons |
| Efgartigimod PH20 SC vs Placebo PH20 SC: serious adverse events | 18 of 147 | 10 of 75 | 222 | NCT04598451 | Trial comparisons |
| Efgartigimod PH20 SC vs Placebo PH20 SC: Number of Pemphigus Vulgaris (PV) Participants Who Achieve Complete Clinical Remission (CR) on Minimal Prednisone Therapy | 44 of 124 | 20 of 66 | 190 | NCT04598451 | Trial comparisons |
| Efgartigimod-efgartigimod PH20 SC vs Placebo-efgartigimod PH20 SC: Proportion of Participants With Pemphigus Vulgaris (PV) and Pemphigus Foliaceus (PF) Who Achieve CRmin | 55 of 101 | 26 of 48 | 149 | NCT04598477 | Trial comparisons |
| Efgartigimod-efgartigimod PH20 SC vs Placebo-efgartigimod PH20 SC: Rate of Treatment Failure in Participants With PV and PF | 3 of 101 | 1 of 48 | 149 | NCT04598477 | Trial comparisons |
| Efgartigimod-efgartigimod PH20 SC vs Placebo-efgartigimod PH20 SC: deaths from any cause | 0 of 101 | 1 of 48 | 149 | NCT04598477 | Trial comparisons |
| Efgartigimod-efgartigimod PH20 SC vs Placebo-efgartigimod PH20 SC: serious adverse events | 16 of 101 | 4 of 48 | 149 | NCT04598477 | Trial comparisons |
| Efgartigimod-efgartigimod PH20 SC vs Placebo-efgartigimod PH20 SC: Proportion of Participants With Pemphigus Vulgaris (PV) Who Achieve CRmin | 47 of 86 | 22 of 41 | 127 | NCT04598477 | Trial comparisons |
| Part A vs Part B: deaths from any cause | 0 of 27 | 0 of 15 | 42 | NCT02704429 | Trial comparisons |
| Part A vs Part B: serious adverse events | 3 of 27 | 0 of 15 | 42 | NCT02704429 | Trial comparisons |
| Ofatumumab vs Placebo: Number of Subjects Who Experienced Sustained Remission on Minimal Steroid Therapy | 0 of 17 | 0 of 18 | 35 | NCT01920477 | Trial comparisons |
| Ofatumumab SC vs Placebo: deaths from any cause | 0 of 17 | 0 of 18 | 35 | NCT01920477 | Trial comparisons |
| Ofatumumab SC vs Placebo: serious adverse events | 1 of 17 | 1 of 18 | 35 | NCT01920477 | Trial comparisons |
| Experimental: Infliximab (Remicade, Revellex) vs Placebo Comparator: Placebo: Participant Response to Treatment at Week 18 | 1 of 10 | 1 of 10 | 20 | NCT00283712 | Trial comparisons |
| Experimental: Infliximab (Remicade, Revellex) vs Placebo Comparator: Placebo: Participant Modified Response Status at Week 18 | 5 of 10 | 3 of 10 | 20 | NCT00283712 | Trial comparisons |
| Experimental: Infliximab (Remicade, Revellex) vs Placebo Comparator: Placebo: Adverse Events Resulting in Treatment Discontinuation | 2 of 10 | 2 of 10 | 20 | NCT00283712 | Trial comparisons |
| Experimental: Infliximab (Remicade, Revellex) vs Placebo Comparator: Placebo: Participants Who Experienced Severe Infectious Complications | 0 of 10 | 0 of 10 | 20 | NCT00283712 | Trial comparisons |
| Experimental: Infliximab (Remicade, Revellex) vs Placebo Comparator: Placebo: Treatment-Related Adverse Events >= Grade 3 On or Before Week 18 | 0 of 10 | 10 of 10 | 20 | NCT00283712 | Trial comparisons |
| Experimental: Infliximab (Remicade, Revellex) vs Placebo Comparator: Placebo: Participants Who Experienced Severe Infusion Reactions | 0 of 10 | 0 of 10 | 20 | NCT00283712 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0008219/comparisons